Intestinal lymphatic targeting of drugs

S.T.P. Pharma Sciences

Volumn 13, Issue 1, 2003, Pages 17-25

  O'Driscoll, C ^a  

^a TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Bioactive excipients; Chylomicrons; GALT; Genetically modified models Lymphomas; HIV; Lipid based vehicles; Mesenteric lymphatics; Vaccines

Indexed keywords

DRUG VEHICLE; EXCIPIENT; HALOFANTRINE; LIPID; PRODRUG; VERAPAMIL;

CONCENTRATION RESPONSE; DNA MODIFICATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG TARGETING; DRUG TRANSPORT; HUMAN; INTESTINE LYMPHATIC TISSUE; LIPOPHILICITY; MESENTERY LYMPH NODE; NONHUMAN; REVIEW;

EID: 0037224816     PISSN: 11571489     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. O'DRISCOLL C. M. - Anatomy and physiology of the lymphatics. - In: Lymphatic Transport of Drugs, W. N. Charman, V. J. Stella, Eds., CRC Press, 1992, pp. 1-35.
2. KHOO S.-M., EDWARDS G.A., PORTER C.J.H., CHARMAN W.N.A. - Conscious dog model for assessing the absorption, enterocyte-based metabolism, and intestinal lymphatic transport of halofantrine. - J. Pharm. Sci., 90, 1599-1607, 2001.
3. PANTALEO G., GRAZIOSI C., DEMAREST J.F., BUTINI L., MONTRONI M., FOX C.H., ORENSTEIN J.M., KOTLER D.P., FAUCI A.S. - HIV infection is active and progressive in lymphoidtissue during the clinically latent stage of disease. - Nature, 362 (6418), 85-89, 1993.
4. PANTALEO G., COHEN O.J., SCHACKER T., VACCAREZZA M., GRAZIOSI C., RIZZARDI G.P., KAHN J., FOX C.H., SCHNITTMAN S.M., SCHWARTZ D.H., COREY L., FAUCI A.S. - Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: implications for antiviral therapy. - Nature Med., 4 (3), 341-345, 1998.
5. GUNTHARD H.F., HAVLIR D.V., FICUS S., ZHANG Z.Q., ERON J., MELLORS J. et al. - Residual HIV-1 RNA and DNA in lymph nodes and HIV RNA in genital secretions and in cerebrospinal fluid after suppression of viremia for 2 years. - J. Infectious Dis., 183 (9), 1318-1327, 2001.
6. KUMAGAI K., TANAKA T., YAMAGATA K., YOKOYAMA N., SHIMIZU K. - Liver metastasis in gastric cancer with particular reference to lymphatic advancement. - Official J. Int. Gastric Cancer Assoc. and Jap. Gastric Cancer Assoc., 4, 150-155, 2001.
7. SKOBE M., HAWIGHORST T., JACKSON D.G., PREVO R., JANES L., VELASCO P. et al. - Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. - Nature Med., 7, 192-198, 2001.
8. CLARK M.A., JEPSON M.A., HIRST B.H. - Exploiting M cells for drug and vaccine delivery. - Adv. Drug Del. Rev., 50, 81-106, 2001.
9. MURANISHI S., FUJITA T., MURAKAMI M., YAMAMOTO A. Potential for lymphatic targeting of peptides. - J. Cont. Rel., 46, 157-164, 1997.
10. PORTER C.J.H. - Drug delivery to the lymphatic system. - Crit. Rev. Drug Carrier Systems, 14, 333-393, 1997.
11. YOSHIKAWA H., MURANISHI S., KATO C., SEZAKI H. Bifunctional delivery system for selective transfer of bleomycin into lymphatics via enteral route. - Int. J. Pharm., 8, 291-302, 1981.
12. RUBAS W., GRASS G.M. - Gastrointestinal lymphatic absorption of peptides and proteins. - Adv. Drug Del. Rev., 7, 15-69, 1991.
13. DAUGHERTY A.L., MRSNY R.J. - Regulation of the intestinal epithelial paracellular barrier. - Pharm. Sci. Technol. Today, 2, 281-287, 1999.
14. JEPSON M.A., SIMMONS N.T., O'HAGAN D.T., HIRST B.H. Comparison of poly(DL-lactide-co-glycolide) and polystyrene microsphere targeting to intestinal M cells. - J. Drug Target., 1, 245-249, 1993.
15. HILLERY A.M., JANI P.U., FLORENCE A.T. - Comparative, quantitative study of lymphoid and non-lymphoid uptake of 60-nm polystyrene particles. - J. Drug Target., 2, 151-156, 1994.
16. ARAUJO L., SHEPPARD M., LOBENBERG R., KREUTER J. Uptake of PMMA nanoparticles from the gastrointestinal tract after oral administration to rats: modification of body distribution after suspensions in surfactant solutions and in olive oil. - Int. J. Pharm., 176, 209-224, 1999.
17. CHEN H., TORCHILIN R., LANGER R. - Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Pharm. Res., 13,1378-1383, 1996.
18. BARGONI A., CAVALLI R., CAPUTO O., FUNDARO A., GASCO M.R., ZARA G.P. - Solid lipid nanoparticles in lymph and plasma after duodenal administration to rats. - Pharm. Res., 5,745-750, 1998.
19. HUSSAIN N., JANI P.U., FLORENCE A.T. - Enhanced oral uptake of tomato lectin-conjugated nanoparticles in the rat. Pharm. Res., 14, 613-618, 1997.
20. HUSSAIN N., JAITLEY V., FLORENCE A.T. - Recent advances in the understanding of uptake of microparticules across the gastrointestinal lymphatics. - Adv. Drug Del. Rev., 50,107-142, 2001.
21. SMITH M.W., THOMAS N.W., JENKINS P.G., MILLER N.G.A., CREMASCHI D., PORTA C. - Selective transport of microparticles across Peyer's patch follicle-associated M cells from mice and rats. - Exp. Physiol., 80, 735-743, 1995.
22. JENKINS P.G., HOWARD K.A., BLACKHALL N.M., BLACKHALL N.W., DAVIS S.S., O'HAGAN D.T. Microparticulate absorption from the rat intestinal. - J. Control. Rel., 29, 339-350, 1994.
23. HERNELL O., STAGGERS J.E., CAREY M.C. - Physicalchemical behaviour of dietary and bilary lipids during intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal lipids during duodenal fat digestion in healthy adult human beings. - Biochemistry, 29, 2041-2056, 1990.
24. STAGGERS J.E., HERNELL O., STAFFORD R.J., CAREY M.C. - Physical-chemical behaviour of dietary and bilary lipids during intestinal digestion and absorption. 1. Phase analysis and aggregation states of model lipid systems patterned after aqueous duodenal contents of healthy adult human beings. Biochemistry, 29, 2028-2040, 1990.
25. PHAN C.T., TSO P. - Intestinal lipid absorption and transport. - Front. Biosci., 6, d299-312, 2001.
26. BROCKMAN H. - Colipase-induced reorganization of interfaces as a regulator of lipolysis. - Colloids and Surfaces B: Biointerfaces, in press, 2002.
27. CHARMAN W.N., STELLA V.J. - Estimating the maximum potential for intestinal lymphatic transport of lipophilic drug molecules. - Int. J. Pharm., 34, 175-178, 1986.
28. PORTER C.J.H., CHARMAN S.A., CHARMAN W.N. - Lymphatic transport of halofantrine in the triple-cannulated anesthetized rat model: Effect of lipid vehicle dispersion. - J. Pharm. Sci., 85, 351-356, 1996.
29. PORTER C.J.H., CHARMAN S.A., HUMBERSTONE A.J., CHARMAN W.N. - Lymphatic transport of halofantrine in the conscious rat when administered as either the free base or the hydrochloride salt: Effect of lipid class and lipid vehicle dispersion. - J. Pharm. Sci., 85, 357-361, 1996.
30. O'DRISCOLL C.M., MYERS R.A., STELLA V.J. - Blood and lymph transport of DDT after oral and parenteral administration to anaesthetised rats. - Int. J. Pharm., 73, 177-183, 1991.
31. KHOO S.-M., PRANKERD R.J., EDWARDS G.A., PORTER C.J.H., CHARMAN W.N. - Physicochemical basis for the extensive intestinal lymphatic transport of a poorly lipid soluble antimalarial, halofantrine hydrochloride, after postprandial administration to dogs. - J. Pharm. Sci., 91(3), 647-659, 2002.
32. SAKAI A., MORI N., SHUTO S., SUZUKI T. - Deacylationreacylation cycle: A possible absorption mechanism for the novel lymphotropic antitumor agent dipalmitoylphosphatidylfluorouridine in rats. - J. Pharm. Sci., 82, 575-578, 1993.
33. CHARMAN W.N., PORTER C.J.H. - Lipophilic prodrugs designed for intestinal lymphatic transport. - Adv. Drug Del. Rev., 19, 149-169, 1996.
34. SEELING A. - A general pattern for substrate recognition by Pglycoprotein. - Eur. J. Biochem., 251, 252-261, 1998.
35. KIM R.B., WANDEL C., LEAKE B., CVETKOVIC M., FROMM M.F., DEMPSEY P.J., RODEN M.M., BELAS F. et al. Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein. - Pharm. Res., 16, 408-414, 1999.
36. REED M.B., SALIBA K.J., CARUANA S.R., KIRK K., COWMAN A.F. - Pghl modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum. - Nature, 403, 906-909, 2000.
37. KITAMURA S., SHIMIZU Y., SHIRAGA Y., YOSHIDA M., SUGIHARA K., SHIGERU O. - Reductive metabolism of p,p'DDT and o,p'-DDT by liver cytochrome P450. - Drug Met. Dispos., 30, 113-118, 2002.
38. O'DRISCOLL C.M. - Lipid-based formulations for intestinal lymphatic delivery. - Eur. J. Pharm., Sci., 15, 405-415, 2002.
39. HAUS D.J., FOGAL S.E., FICORILLI J.V., PRICE C.A., ROY T., JAYARA A.A., KEIRNS J.J. - Lipid-based delivery systems for improving the bioavailability and lymphatic transport of a poorly water-soluble LTB4 inhibitor. - J. Pharm. Sci., 87, 164-169, 1998.
40. CALIPH S.M., CHARMAN W.N., PORTER C.J.H. - Effect of short-, medium-, and long-chain fatty acid based vehicles on the absolute oral bioavailability and intestinal lymphatic transport of halofantrine and assessment of mass balance in lymphcannulated and non-cannulated rats. - J. Pharm. Sci., 89, 1073-1084, 2000.
41. NERURKAR M.M., BURTON P.S., BORCHARDT R.T. - The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarised efflux system. - Pharm. Res., 13, 528-534, 1996.
42. NERURKAR M.M., HO N.F.H., BURTON P.S., VIDMAR T.J., BORCHARDT R.T. - Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. - Pharm. Res., 86, 813-821, 1997.
43. DINTAMAN J.A., SILVERMAN J.A. - Inhibition of P-glycoprotein by D-α-tocopherol polyethylene glycol 1000 succinate (TPGS). - Pharm. Res., 16, 1550-1556, 1999.
44. KABANOV A.V., BATRAKOVA E.V., ALAKHOV V.Y. - Pluronic block copolymers as novel polymer therapeutics for drug and gene delivery. - J. Contr. Del., in press, 2002.
45. GRIFFIN B.T., O'DRISCOLL C.M. - Targeting of saquinavir to the intestinal lymphatics in the rat-the influence of P-glycoprotein and cytochrome P450 modulators. - AAPS PharmSci., 3, T3175, 2001.
46. FIELD F.J., BORN E., CHEN H., MURTHY S., MATHUR S.N. - Esterification of plasma membrane cholesterol and triacylglycerol-rich lipoprotein secretion in Caco-2 cells: possible role of p-glycoprotein. - J. Lipid Res., 36, 1533-1543, 1995.
47. O'DRISCOLL C.M. - The use of the Caco-2 model to investigate biochemical and metabolic aspects of lipid absorption. - Bull. Tech. Gattefossé, 91, 41-46, 1998.
48. SEEBALLUCK F., ASHFORD M.B., O'DRISCOLL C.M. - The effects of synthetic and naturally occurring surfactants on lipid absorption and metabolism in the Caco-2 cell model. - AAPS Pharm Sci., 3, R5134, 2001.
49. O'DRISCOLL C.M. - Micellar solubilisation/self-emulsifying systems for improved absorption of drugs. - In: Formulation of Poorly-Available Drugs for Oral Administration (Minutes of the Eur. Sympos.), Editions de Santé, Paris, 1996, pp. 126-151.
50. McGREGOR K.J., EMBLETON J.K., LACY J.E., PERRY E.A., SOLOMON L.J., SEGGER H., POUTON C.W. - Influence of lipolysis on drug absorption from the gastrointestinal tract. Adv. Drug Del. Rev., 25, 33-46, 1997.
51. Zangenberg N.H., Mullertz A., Kristensen H.G., Hovgaard L. A dynamic in vitro lipolysis model. I. Controlling the rate of lipolysis by continuous addition of calcium. - Eur. J. Pharm. Sci., 14, 115-122, 2001.
52. SEK L., PORTER C.J.H., KAUKONEM A.M., CHARMAN W.N. - Evaluation of the in vitrodigestion profiles of long and medium chain glycerides and the phase behaviour of their lipolytic products. - J. Pharm. Pharmacol., 54, 29-41, 2002.
53. MEANEY C.M., O'DRISCOLL C.M. - A comparison of the permeation enhancement potential of simple bile salt and mixed bile salt:fatty acid micellar systems using the Caco-2 cell culture model. - Int. J. Pharm., 207, 21-30, 2000.
54. KERNEIS S., BOGDANOVA A., KRAEHENBUHL J.-P., PRINGAULT E. - Conversion by Peyer's patch lymphocytes of human enterocytes into M cells that transport bacteria. - Science, 277, 949-952, 1997.
55. FIELD F.J., ALBRIGHT E., MATHUR S.N. - Regulation of triglyceride-rich lipoprotein secretion by fatty acids in Caco-2 cells. - J. Lipid Res., 29, 1427-1437, 1988.
56. VAN GREEVENBROEK M.M.J., VOORHOUT W.F., ERKELENS D.W., VAN MEER G., DE BRUIN T.W.A. - Palmitic acid and linoleic acid metabolism in Caco-2 cells: different triglyceride synthesis and lipoprotein secretion. - J. Lipid Res., 36, 13-24, 1995.
57. VAN GREEVENBROEK M.M.J., VAN MEER G., ERKELENS D.W., DE BRUIN T.W.A. - Effects of saturated, mono-, and polyunsaturated fatty acids on the secretion of apo B containing lipoproteins by Caco-2 cells. - Atherosclerosis, 121, 139-150, 1996.
58. VAN GREEVENBROEK M.M.J., ERKELENS D.W, DE BRUIN T.W.A. - Caco-2 cells secrete two independent classes of lipoproteins with distinct density: effect of the ratio of unsaturated to saturated fatty acids. - Atherosclerosis, 149, 25-31, 2000.
59. HUSSAIN M.M. - A proposed model for the assembly of chylomicrons. - Atherosclerosis, 148, 1-15, 2000.
60. PORTER C.J.H., CHARMAN W.N. - Uptake of drugs into the intestinal lymphatics after oral administration. - Adv. Drug Del. Rev., 25, 71-89, 1997.
61. LUCHOOMUN J., HUSSAIN M.M. - Assembly and secretion of chylomicrons by differentiated Caco-2 cells. - J. Biol. Chem., 274, 19565-19572, 1999.
62. TSO P., BUCH K.L., BALINT J.A., RODGERS J.B. - Maximal lymphatic trigiyceride transport rate from the rat small intesine. - Am. J. Physiol., 242, G487-G497, 1982.
63. TSO P., GOLLAMUDI S.R. - Pluronic L-81: a potent inhibitor of the transport of intestinal chylomicrons. - Am. J. Physiol., 247, G32-G36, 1984.
64. ZHENG S., EE L., YAU L., HUI D., TSO P. - A study of the uptake and lymphatic transport of lipid in the mouse. - Gastroenterology, 114, A916, 1998.
65. O'DRISCOLL C.M. - Genetically modified models aid understanding of absorption mechanisms from oral lipid-based drug delivery systems. - Formulink, Gattefossé Newsletter, Editorial, 7, 1, 4, 2002.
66. OUDE ELFERINK R.P.J., TYTGAT G.N.J., GROEN A.K. - The role of mdr2 P-glycoprotein in hepatobiliary lipid transport. FASEB J., 11, 19-28, 1997.
67. WANG D.O.-H., LAMMERT F., PAIGEN B., CAREY M. C. Hyposecretion of biliary phospholipids (PL) significantly decreases the intestinal absorption of cholesterol (Ch) in Mdr2 (-/-) and (+/-) mice. - Gastroenterology, 114, A913, 1998.
68. TSO P., DRAKE D.S., BLACK D.D., SABESIN S.M. - Evidence for separate pathways of chylomicron and very low-density lipoprotein assembly and transport by rat small intestine. - Am. J. Physiol., 247, G599-G610, 1984.
69. TSO P., BALINT J.A. - Formation and transport of chylomicrons by enterocytes to the lymphatics. - Am. J. Physiol., 250, G715-G726, 1986.
70. NG V.L., ZHENG S., DAVIDSON N.O., TSO P. - Lymphatic transport of lipids in apobec-1 knockout mice. - Gastroenterology, 118, A662, 2000.
71. KENDRICK J.S., CHAN L., HIGGINS J.A. - Superior role of apolipoprotein B48 over apolipoprotein B100 in chylomicron assembly and fat absorption: an investigation of apobec-1 knock-out and wild-type mice. - Biochem. J., 356, 821-827, 2001.
72. WANG D.O-H., PAIGEN B., CAREY M.C. - Genetic factors at the ente rocyte level account for variations in intestinal cholesterol absorption efficiency among inbred strains of mice. - J. Lipid Res., 42, 1820-1830, 2001.